Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Andexxa (andexanet alfa), the only specific anti-Xa reversal agent, has been withdrawn from the US market on December 22, 2025.
It was marketed for the reversal of Rivaroxaban and Apixaban.
The theory was great, but it was very expensive and had a higher thrombotic risk than when PCC was used for reversal.
Below is the announcement on the FDA website.
As far as I know, it is still being sold and used in Europe, but I can not see this continuing.
There is nothing on the EMA website.
Also, rather surprisingly, there is no mention of this on the AstraZeneca US or UK websites about this.
Do their medical communication teams not work in the second part of December?”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 2, 2026, 12:53José Antonio García Erce: The National Transplant Organization Published the 2024 Report of the Global Observatory on Donation and Transplantation
-
Jan 2, 2026, 12:48Reza Shojaei: Stepping into 2026 – Your Daily Commitment Saves Lives
-
Jan 2, 2026, 09:36Shashank K R on The Use of Lumbrokinase from Eudrilus eugeniae
-
Jan 2, 2026, 09:20Rehan Khan Explores Clopidogrel
-
Jan 2, 2026, 09:06Gokhan Ozdemir on Thrombophilia in Young Ischemic Stroke
-
Jan 2, 2026, 08:47Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
-
Jan 2, 2026, 03:52Abdul Mannan: When Gender Bias Becomes a Diagnostic Error – Inherited Bleeding Disorders are Still Being Missed
-
Jan 2, 2026, 03:51Samwel Mikaye: Thrombocytopenia in Pregnancy
-
Jan 2, 2026, 03:50Marc Carrier: Clinicians Working With Cancer Patients on DOACs. We Need Your Expertise!